Through enhanced permeability and retention (EPR), aPD-L1/ICG@NP passively accumulates at the tumor site and is activated to release aPD-L1 in high MMP-2-expressing tumors to block PD-L1 on tumor cells. Here, CD274 is linked to neoplasm.